 
IGT Systems EPD CIP Template  Page: 1 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 1 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
  
 
 
 
PROOF : Evaluating the Performance of the KODEX-E PD 
CRyOballoon Occlusion Feature in patients with atrial 
fibrillation  (CLN-KODEX-0019) 
Clinical Investigation Plan 
 
 
Protocol version: 4 
Clinicaltrials.gov [STUDY_ID_REMOVED] 
Issue Date: 15-Jul-20 
Clinical Study Sponsor: EPD Solutions (a/k/a Philips Me dical Systems Nederland B.V.) 
Veenpluis 6 
5684 PC, Best The Netherlands 
(Revision History); Version 1.0  2019 Dec 10 
 Version 2.0 2020 Jan 21 
 Version 3.0 2020 Jul 15 
 Version 4.0  2022 Jan 31 
  
 
 
  
 
IGT Systems EPD CIP Template  Page: 2 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 2 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 Investigator Protocol Agreement Page 
 
 I confirm agreement to conduct the study in compliance with the protocol. 
 I agree to conduct the study in compliance with the protocol, International Conference on 
Harmonization (ICH) Guidelines for Good Clinical Practice (GCP), patient privacy regulations and other applicable regulatory requirements. 
 I acknowledge that I am responsible for overall study conduct. I agree to personally conduct or 
supervise the described clinical study. 
 I agree to ensure that all associates, colleagues and employees assisting in the conduct of the study are 
informed about their obligations. Mechanisms are in place to ensure that site staff receive the 
appropriate information throughout the study. 
 I agree to provide all required data and agree to source document verification of study data with 
patient’s medical records.   
 I agree to report serious and/or unanticipated and/or device related adverse even ts to Sponsor within 24 
hours from occurrence. 
  
Site Name   
   Principal Investigator Name   
 
   
Signature  Date 
 
 
  
 
IGT Systems EPD CIP Template  Page: 3 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 3 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
  STUDY COLLABORATORS  
 
  Coordinating Investigators Ronald Berger 
Johns’ Hopkins University 600 North Wolfe Street 
Halsted 570 
Baltimore, MD 21287, USA Carlo De Asmundis 
UZ Brussel Laarbeeklaan 101 
1090 Jette Brussel, Belgium 
 rberger@jhmi.edu  
+1 410 614 2751 Carlo.Deasmundis@uzbrussel.be   
+32(0)494 92 05 84 
 
IGT S ystems EPD CIP Tem plate  Pa ge: 4 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 4 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 TABLE OF CONTENTS  
  
 
Study Collaborators............................................................................................................ ....................... 3  
Table of Contents ............................................................................................................. ......................... 4  
Study Synopsis ................ ................ ................ ................. ................ ................ ............... .......................... 7  
1. Background and Rationale ...................................................................................................... ........ 11 
 Overview of Disease ........................................................................................................... ..... 11 
 Arrhythmias ............................................................................................................ 11  
 Current Treatment Options ..................................................................................... 11  
 Cryoballoon Ablation Therapy and Technology .................................................... 12  
 KODEX-EPD System ............ ................ ................ ............. .............. ............. ............. .............  12 
 Description of the KODEX-EPD System .......... ................ ................ ............. ........ 12 
 Intended Use ........................................................................................................... 14  
 Limitations for use .................................................................................................. 14  
 Exposure to Study Device ....................................................................................... 14  
 Study design justification .................................................................................................... ..... 15 
 (Pre)Clinical Studies with the KODEX-EPD Syst em ............. ............. .............. ..... 15 
 Relevant Clinical Studies ........................................................................................ 15  
2. Experimental Plan ............................................................................................................. .............. 16  
 Study Objectives............................................................................................................... ........ 16 
 Study Design .................................................................................................................. .......... 16  
 Study Schematic ...................................................................................................... 16  
 .............................................................................................................................. ................. 16  
 .............................................................................................................................. ................. 16  
 Primary Endpoints........... ................ ................ ................ ................ ................ ........ 17 
 Secondary and Exploratory Endpoints ............ ................ ................ ................ ........ 17 
 Study Duration ........................................................................................................ 17  
 Study Centers ................................................................................................................. .......... 17  
 Number of patients ............................................................................................................ ....... 17 
 Subject Selection and Enrollment ............................................................................................ 1 7 
 Study Population and Eligibility ............................................................................. 17  
 Inclusion Criteria..................................................................................................... 18  
 Exclusion Criteria ................................................................................................... 18  
 Withdrawal .............................................................................................................. 18  
 Study Procedures .............................................................................................................. ........ 18 
 Screening and Informed Consent ............................................................................ 18  
 Intervention ............................................................................................................. 19  
 
IGT S ystems EPD CIP Tem plate  Pa ge: 5 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 5 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 
 Follow up ................................................................................................................ 21  
 Discharge & End of Study ........... ................ ................ ................ ................ ........... 21  
 After End of Study .................................................................................................. 21  
 Schedule of Assessments ........................................................................................ 21  
 Standardization of Study Procedures ...................................................................... 22  
3. Risk/Benefit Analysis ......................................................................................................... ............ 23  
 Potential Risk to the Subject ................................................................................................. ... 23 
 Potential Benefits to the Subject ............................................................................................. . 23 
 Benefit-Risk Rationale ........................................................................................................ ..... 23 
4. Safety Data Collection, Recording and Reporting ..... ..................................................................... 24  
 Definitions ................................................................................................................... ............. 24  
 Adverse Events (AE) .............................................................................................. 24  
 Adverse Device Effect (ADE) ................................................................................ 24  
 Serious Adverse Event (SAE) ................................................................................. 24  
 Serious Adverse Device Effect (SADE) ................................................................. 25  
 Unanticipated Serious Adverse Device Event (USADE) ....................................... 25  
 Device Deficiencies ................................................................................................ 25  
 Adverse Event Classification .................................................................................................. . 25 
 Severity Classification ............................................................................................ 25  
 Relationship Classification ..................................................................................... 26  
 Outcome Classification ........................................................................................... 26  
 Reporting ..................................................................................................................... ............. 27  
 Reporting of AEs and ADEs ................................................................................... 27  
 Reporting of SAEs SADEs and USADEs............................................................... 27  
5. Statistical Consideration ..................................................................................................... ............ 28  
 Study Endpoints ............................................................................................................... ........ 28 
 Primary Endpoints........... ................ ................ ................ ................ ................ ........ 28 
 Secondary Endpoints....... ................ ................ ................ ................ ................ ........ 28 
 Analysis Sets ................................................................................................................. ........... 28  
 Sample Size Considerations .................................................................................................... . 29 
 Statistical Analysis .......................................................................................................... ......... 29  
 General Approach/Considerations .......................................................................... 29  
 Analysis of Key Study Endpoints ........................................................................... 29  
 Data justification ............................................................................................................ .......... 29  
 Missing Data ........................................................................................................... 29  
 Deviations ............................................................................................................... 30  
6. Study Conduct ................................................................................................................. ................ 30  
 
IGT S ystems EPD CIP Tem plate  Pa ge: 6 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 6 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 
 Statement of Compliance ....................................................................................................... .. 30 
 Source Documents .............................................................................................................. ...... 30 
 Data Handling and Record Keeping ......................................................................................... 31  
 Device Accountability............................................................................................. 32  
 Investigator Responsibilities ....... ................ ................ ................ ................ .............. ............ ... 32 
 Delegation of Responsibility ..... ................. ............. ............. .............. ............. ........ 34 
 Protocol Deviations ................................................................................................. 34  
 Sponsor Responsibilities ............. ................ ................ ................ ................ .............. ........... .... 34 
 Confidentiality ........................................................................................................ 34  
 Monitoring .............................................................................................................. 35  
 Insurance ................................................................................................................. 35  
 Amendments to the CIP .......................................................................................... 35  
7. Publications .................................................................................................................. ................... 35  
8. General Information ........................................................................................................... ............. 36  
 Study Contact Information ..................................................................................................... .. 36 
 Retention of Records .......................................................................................................... ...... 36 
 Study Completion/Termination or Suspension of th e Study ............. ................ ............. .......... 36  
 Reporting Timelines ................................................................................................ 37  
 Subject Follow up ................................................................................................... 37  
 Blinding ................................................................................................................... 37  
9. Reference ..................................................................................................................... ................... 38  
 
  
 
IGT Systems EPD CIP Template  Page: 7 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 7 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 Study Synopsis 
STUDY TITLE  PROOF : Evaluating the Performance of the KODEX-EPD 
CRyOballoon Occlusion Feature in patients with atrial fibrillation 
STUDY PHASE  Post-market 
INVESTIGATIONAL 
PRODUCT  KODEX-EPD System, KODEX-EPD data collection accessories 
INDICATION  Patients with Atrial Fibrillation 
OBJECTIVE  Performance of KODEX-EPD PV occlusion feature as compared to 
conventional venographic method of fluoroscopy with contrast dye 
in cryoballoon procedures that is used to guide the procedure. Performance will be calculated in terms of accuracy, sensitivity, 
specificity and positive and nega tive predictive values. In the 
blinded arm of the study, the operator will be blinded for the PV occlusion data on the KODEX-EPD system and this data will not be 
used for clinical guidance.  
STUDY DESIGN  Prospective, multi-center, non-rand omized, open label, double arm 
study 
# OF SUBJECTS  The study will include a maximum of 20 patients per center at 2 
centers in the blinded to KODEX ar m of the study. An additional 25 
patients will be included at UZ Brussel in the KODEX guided arm 
of the study. 
 
STUDY DURATION  18 months 
STUDY POPULATION  Arrhythmia patients scheduled to undergo a cryo balloon ablation 
procedure for their atrial fibrillatio n. Both male and female subjects 
who meet all eligibility criteria a nd give written informed consent 
will be enrolled in the study.  
Inclusion criteria: 
1. Subject must be aged >18 years. 
2. Subject must have signed a written Informed Consent form to 
partici pate in the stud y, prior to an y stud y related procedures. 
 
IGT Systems EPD CIP Template  Page: 8 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 8 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 3. Subject must be willing to comply with the protocol 
requirements. 
4. Subject receives a de novo ab lation procedure for treatment 
of atrial fibrillation. 
Exclusion criteria;  
Pregnant women. 
STUDY VISIT SCHEDULE  
AND PROCEDURES  This is an acute study with no follow-up. 
Before the procedure (Baseline) : 
1. Eligibility according to inclusion and exclusion criteria 
2. Obtaining signed Informed Consent Form (ICF) 
3. Demographics 
4. Medical history 
5. Physical examinations 
6. Concomitant medications 
7. Presence/history of atrial fibrillation 
8. Previous and current treatments of atrial fibrillation 
During procedure: 
1. Delivery of standard therapy. The study device will be used 
in the cryoballoon ablation procedure according to the instructions for use. PV occlusion will be assessed with the 
KODEX-EPD PV occlusion feature.  
‐ Blinded Arm; The physician will be blinded for the 
KODEX-EPD occlusion data and use conventional 
venographic method of fluoroscopy with contrast dye to 
guide the procedure. 
‐ KODEX guided Arm; the physician will use the KODEX-
EPD occlusion data to guide the procedure 
2. Confirmation of therapy. Confir m PV isolation using standard 
practice. 
3. Adverse events Reporting.  
PRIMARY ENDPOINTS  1. The  accuracy, sensitivity,  specificity and positive and 
negative predictive values of the KODEX-EPD PV occlusion feature as compared to conventional venographic method of fluoroscopy with contrast dye that will be used to 
guide the procedure.  
2. The success of the freeze when freeze is initiated based on 
the assessment of the KODEX-EPD PV occlusion feature as 
compared to the success of the freeze when freeze is 
 
IGT Systems EPD CIP Template  Page: 9 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 9 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 initiated based on the assessme nt with fluoroscopy and 
contrast dye. 
SECONDARY / 
EXPLORATORY 
ENDPOINTS  Procedure data collection: 
 KODEX-EPD data collection 
 Fluoroscopy system data collection 
 Fluoroscopy time 
 Fluoroscopy dose 
 Number of contrast dye injections 
 Contrast dye volume 
 Information on durability  of the PV isolation. 
 Time to isolation (TTI)/Success of Isolation 
 Number of ablations per vein 
 Procedure time (skin to skin) 
 
SPONSOR  EPD Solutions is the sole study sponsor.  This study will be 
conducted according to US 21 CFR 11, 50, 54, 56, 812, ISO 14155: 
2020, the ICH Guidelines for GCP, the Declaration of Helsinki (2013) and all other applicable local and national regulations.  The study will be registered on www.clinicaltrials.gov .    
 
 
IGT Systems EPD CIP Template  Page: 10 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 10 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 Acronyms and Definitions 
AE Adverse Event 
CRF Case Report Form 
EMR electronic medical record 
EP electrophysiology 
ESI Event of Special Interest 
HU Healthcare Utilization  
ICF Informed Consent Form 
SAE Serious Adverse Event 
USADE Unanticipated Serious Adverse Device Effect 
 
  
 
IGT S ystems EPD CIP Tem plate  Pa ge: 11 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 11 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 1. BACKGROUND AND RATIONALE  
 Overview of Disease 
 Arrhythmias 
Cardiac arrhythmias are common and produce considerable morbidity and mortality and are 
challenging to treati. Symptoms such as dizziness, palpitation s, and syncope are frequent complaints 
encountered by family physicians, internists, and ca rdiologists. In contrast to these ubiquitous 
complaints, which are generally benign, sudden cardiac death remains an important public health 
concern. Statistics from the Centers for Disease Co ntrol and Prevention (CDC) have estimated sudden 
cardiac death rates at more than 600,000 per year. Up to 50% of patients have sudden death as the first 
manifestation of cardiac diseaseii.  
Arrhythmias are one of the most complexes, insufficiently studied, and therefore one of the most urgent 
problems of modern cardiology. With a wide introd uction in the practice of ECG monitoring by Holter 
as well as the use of individual recorders of electr ocardiogram data appeared indicating a much higher 
frequency of cardiac arrhythmiasiii. 
Enormous advances in arrhythmia management have occurred over the 60 years, but important 
challenges remain. Challenges in diagnosis, detection,  and risk-stratification include difficulties in 
separating benign from high-risk syncope and pin pointing the underlying ca uses and inadequate 
identification of sudden-death risk. 
As of 2012, approximately 4.3 million Americans experienced some form of cardiac arrhythmia. 
Annually, 5,750,440 individuals experienced cardiac arrhythmia in the US. Total direct annual 
healthcare cost of cardiac arrhythmia summed up to $US67.4 billion.  Cardiac arrhythmias represent a 
substantial economic burden in the US, especially for the older adult populationiv. 
 Current Treatment Options 
Pharmacologic therapy for arrhythmia is widely used however catheter ablation offers encouraging 
results in the treatment of most cardiac arrhythmias and is considered as a first line therapy by international guidelines.
v,vi Furthermore in the treatm ent of Atrial Fibrillation (AF) catheter ablation is 
considered superior regarding freedom of arrhythm ia recurrence compared to anti-arrhythmic drug 
therapy.vii,viii,ix 
Current catheter-based therapy utilizes cardia c 3D mapping and navigation systems that were 
introduced more than 20 years ago and allow location  of the ablation device within a reconstruction of 
the heart anatomyx,xi,xii,xiii. However, technical limitations specific to each available 3D mapping 
system, such as variability in catheter tip location sensing, alternating location reliability throughout the 
procedure, and the use of costly specialized cathe ters and additional hardware (e.g. magnets placed 
under the operating table, pose limitations of these systems. Furthermore, all available systems provide 
only an estimate of each individual anatomy, as they do not provide high-quality, real-time 
 
IGT S ystems EPD CIP Tem plate  Pa ge: 12 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 12 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 visualization of anatomical structures, but merely a low-resolution reconstruction. In order to obtain 
more information and a precisely detailed anatom y, time consuming and often costly additional 
imaging such as fluoroscopy, angiography, echoca rdiography and even pre-procedural computer 
tomography (CT) and magneti c resonance imaging (MRI) is required in many casesxiv.  
In conclusion the current procedures are relative ly long, considered highly complex and require 
substantial expertise. In addition specialized catheters  and additional hardware is required. The Sponsor 
has identified these challenges and has developed the KODEX - EPD system to address them successfully. 
 Cryoballoon Ablation Therapy and Technology 
Pulmonary vein isolation (PVI), by catheter ablation, represents the current treatment for drug-resistant 
AFxv. Due to its ease of use, fast procedures and du rability of lesions in a high percentage of PVs 
leading to excellent clinical outcome, Cryoballoon Ab lation is a recognized ablation method in patients 
with atrial fibrillationxvi. However, cryoballoon ablation requires extensive fluoroscopic guidance to 
position the balloon catheter at the pulmonary veins often leading to prolonged  radiation exposure and 
possible contract induced kidney injury. 
 KODEX-EPD System 
 Description of the KODEX-EPD System 
The KODEX - EPD system is an open platform that uses any validated EP catheter to create real-time 
3D images of the human heart. The KODEX-EPD system takes advantage of the unique dielectric 
properties of biological tissue by inducing anisotropic electrical fields within the patients´ body and 
measuring the resultant subtle electrical field differences  on the catheter electrodes as they move in the 
hearts´ chambers. The anisotropic fields are induce d by one or multiple sources such as external 
sensors on the body surface and the diagnostic and/or  an ablation catheter. The system receives and 
analyzes the electrical field transmission and reflection from all catheter electrodes as they are 
manipulated in the cardiac chambers . Structures such as the endocard ial atrial surface, cardiac veins, 
and heart valves cause marked gradients in the electrical field. This “bending of the electrical field” is 
sensed by the system and used to calculate the geom etric characteristics of the three-dimensional (3D) 
image. With this technique, the KODEX-EPD System collects anatomic information, without 
immediate physical surface contact, a few millimeters ahead of the catheter electrodes, resulting in a 
certain degree of “far-field imaging”. The catheter serves as an internal distance ruler for scaling of the 
geometry by comparing the known inter electrode spacing versus the voltage difference between the 2 
electrodes. The system records a specific set of elec trical field descriptors for each specific position of 
the catheter within the cardiac anatomy and can thereby determine relative positions and distances 
between locations within the chamber. At each lo cation, the electrical field descriptors that the 
KODEX-EPD System acquires are used to reconstruct the chamber geometry.xvii  
 
IGT S ystems EPD CIP Tem plate  Pa ge: 13 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 13 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 
 Study device 
The KODEX-EPD system is manufactured by; 
 
Philips Medical Syst ems Nederland B.V. 
Veenpluis 6 
5684 PC Best 
The Netherlands 
 
The study device hardware consists of a; 
 Processing Unit (version 1.2) 
 Workstation 
 Body Surface pin box 
 Diagnostic Catheter pin box (2x) 
 Recording system pin box (2x) 
 Foot Pedal 
 
 
 
 
 
The most recent commercialized version of the software will be used for the purpose of this study. Currently this is so ftware version 1.4.8 
 
The KODEX-EPD system is designed to be used with validated commercially available diagnostic and therapeutic catheters. The KODEX-EPD System is supported with dedicated KODEX-EPD sensors and 
catheters activation keys for RF and Cryo ablation interventions. 
 
  
Figure 2: Procedural Disposables 
The KODEX - EPD system interfaces with the following commercially available components and 
devices: 
1. Display: shows in real-time, and throughout the proced ure, the cardiac chamber’s geometry and all 
indwelling catheters. 
Figure 1: System Overview 
 
IGT S ystems EPD CIP Tem plate  Pa ge: 14 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 14 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 2. RF generator: commercially available RF generators can be connected to the KODEX - EPD 
system PU, which is then connected to the ablati on catheter. The following  commercially available 
RF generators have been tested with the KODEX - EPD system PU: 
‐ KODEX - EPD RF Ablation System 
‐ Stockert 70 (Biosense Webster) RF Generator 
‐ SmartAblate (Biosense Webster) RF Generator 
‐ Maestro 4000 (Boston Scientific) RF Generator 
3. Standard EP diagnostic and ablation catheters: for a full list of commercially available 
compatible catheters, refer to KODEX - EPD system List of Compatible Catheters. 
4. Recording system (incl udes pacer connection): commercially available recording systems, such 
as Prucka CardioLab EP Recording System (G eneral Electric) or LABSYSTEM PRO (Boston 
Scientific). 
 KODEX-EPD system updates. 
The Instructions for use (IFU) will be provided containing the information on the most current software 
and hardware versions that will be used. Please  note that the CIP will not be updated if the 
hardware/software version is updated unless the update results in; 
- an updated clinical workflow described in this CIP; 
- an updated benefit-risk analysis; 
- an update to the study design; 
- an update to the data to be collected; 
- any other update that would affect the ex ecution of this clinical investigation. 
 
 Intended Use 
The KODEX-EPD system has received FDA approval and CE mark for creating real-time 3D images 
of the human heart using validated commercially av ailable diagnostic and therapeutic catheters. 
For the purpose of this study we will be using the KODEX-EPD system in its intended use as described in the User Manual 
 Training and Experience 
Trained sponsor personnel will be responsible for the set-up of the KODEX-EPD system and will 
operate the system during the procedure. Physicians  completing the EP procedures will have received 
training on the KODEX-EPD system prior to including the first subject in the study. This training is 
outside the scope of the study. 
 Limitations for use 
There are no special clinical situations that could potentially affect or limit the system performance and 
accuracy.  
  Exposure to Study Device  
The KODEX-EPD System is used to assist the physician during cardiac ablation procedures in patients 
with a cardiac arrhythmia. The patient will be connected to the KODEX-EPD system via the KODEX-
 
IGT S ystems EPD CIP Tem plate  Pa ge: 15 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 15 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 EPD sensors shown in Figure 2. The duration of expo sure to the Study device for both the operator and 
patient will be the length of the cardiac ablation procedure. 
 Study design justification 
 (Pre)Clinical Studies with the KODEX-EPD System 
The system’s measurement and localization capabilities have been validated and the location accuracy 
and distance score measurements demonstrated that the system is highly accurate, whereas the DURABLE-I clinical study demonstrated safety and efficacy of the KODEX-EPD system. Another study demonstrated that the 3D image quality generated by the KODEX-EPD system is noninferior to CARTO 3 (Biosense Webster) and accurately detects catheter location
xviii. Clinical data to date has not 
demonstrated any adverse device effects. 
 Cryo Occlusion feature: 
The performance of the Cryo Occlusion feature was validated by means of retrospective analysis of a 
database of KODEX files from routine cases for which the occlusion status on venography was available as ground truth. For each occlusion ev ent from the database the occlusion status on KODEX 
was determined with the final version of the KODEX occlusion algorithm and compared against the 
corresponding occlusion status on venography as grou nd truth. The accuracy of the Cryo Occlusion 
feature for the baseline workflow was 92.1%, and for the injection workflow 90.4%, both of which 
exceed the pre-defined acceptance criteria of ≥ 90%. The clinical acceptability of the workflow of the 
Cryo Occlusion feature was evaluated by replay of a subset of the KODEX files (n=10) from the 
database with a final version of KODEX software. During replay of these cases, five clinical specialists 
filled in a questionnaire in which they each answered  questions related to four user requirements of the 
Cryo Occlusion workflow and provided a score using a 5-point Likert scale. The average scores were 
4.0, 4.4, 3.6, and 3.6, and ther eby the test was passed because the pre-defined acceptance criteria was 
≥3. 
 Relevant Literature on th e KODEX-EPD System Cryoballoon Occlusion feature  
Several manuscripts on the occlusion feature have been published to date, xix,xx,xxi,xxii. reporting that the 
KODEX-EPD Occlusion feature is safe, feasible, and effective in assessing the degree of PV occlusion 
during AF cryoablation.  
 Study Justification 
Current clinical studies on the KODEX-EPD occlusion feature have reported on the safe and effective 
use of the system in standard practice. However, the performance of the KODEX-EPD occlusion feature has not been evaluated using a standardized  workflow in a blinded setting in a homogenous 
patient group. Furthermore, in an effort to minimi ze therapy, a direct comparison between the success 
of the freeze when initiating therapy based on the oc clusion feature vs the assessment of occlusion by 
fluoroscopy has not been evaluated.  The study desi gn indicates a post-market interventional clinical 
 
IGT S ystems EPD CIP Tem plate  Pa ge: 16 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 16 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 
ICF 
Screening 
Pulmonary Vein 
Occlusion with a partial leak on the venogram 
resulting in ablation. 
Occlusion ; no visible leak on the veno gram 
 Large (common) PV ostium > 28mm 
identified with venography and KODEX-EPD 
Exceeding threshold for DTS, DTM or DTO 
on KODEX -EPD
Achieve movement during injection, double 
injection, incorrect timing of injection on 
KODEX-EPD 
Figure 3; Study Schematic  investigation to evaluate the endpoints of the stud y. No follow-up is foreseen ensuring a minimal 
burden to the subjects participating in the study.  
2. EXPERIMENTAL PLAN 
 Study Objectives 
The study objective is to evaluate the performance of the KODEX-EPD PV occlusion feature as 
compared to conventional venographic method of  fluoroscopy with contrast dye in cryoballoon 
procedures that is used to guide the procedure. Pe rformance will be calculated in terms of accuracy, 
sensitivity, specificity and positive and negative pred ictive values. In the blinded arm of this 2-armed 
study, the operator will be blinded for the PV o cclusion data on the KODEX-EPD system, and this data 
will not be used for clinical guidance. In the KODEX guided arm the operator will use the KODEX-
EPD system occlusion data to guide the procedure. 
 
 Study Design 
 Study Schematic 
  
 
 
 
     
 
The Cryoballoon procedure consists of the isolati on and ablation of the pulmonary veins (PVs). The 
number of PVs and occlusion tests per PV depend s on several factors including patient anatomy. 
Therefore, data from the KODEX-EPD PV Occlusion feature will be evaluated as a separate set of data 
for each occlusion test and for each pulmonary vein. Data from a PVI where the diameter of the 
(common) PV ostium > 28mm, or when the threshold for Distance to Shadow (DTS), Distance to Mesh 
(DTM) or Distance to Ostium (DTO ) is exceeded, or when the Achieve catheter is moving during the Cryoballoon procedure 
 
IGT S ystems EPD CIP Tem plate  Pa ge: 17 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 17 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 injection, there is a double injection or an incorrect timing of the injection, will not be included in the 
primary endpoint analysis. 
 Primary Endpoints 
1. The accuracy, sensitivity, specificity and pos itive and negative predictive values of the 
KODEX-EPD PV occlusion feature as compared to conventional angiographic method of 
fluoroscopy with contrast dye that will be used to guide the procedure. 
2. The success of the freeze when freeze is initia ted based on the assessment of the KODEX-EPD 
PV occlusion feature as compared to the succe ss of the freeze when freeze is initiated based on 
the assessment with fluoroscopy and contrast dye. 
 Secondary and Exploratory Endpoints 
Procedure data collection: 
 KODEX-EPD data collection 
 Fluoroscopy system data collection 
 Fluoroscopy time 
 Fluoroscopy dose 
 Number of contrast dye injections 
 Contrast dye volume 
 Time to isolation (TTI)/Success of Isolation 
 Number of ablations per vein 
 Procedure time (skin to skin) 
 Study Duration 
The study enrolment is expected to take 1.5 years. The study has no F/Up therefore the total duration is 
expected to be 1.5 years. 
 Study Centers 
In total Two (2) centers; Johns Hopkins University  in Baltimore, USA and UZ  Brussel in Brussel, 
Belgium will participate in the study 
 Number of patients 
A maximum of 20 patients per center will be include d in the blinded to KODEX arm of the study. An 
additional 25 patients will be included at UZ Brussel in the KODEX guided arm of the study. 
 Subject Selection and Enrollment 
 Study Population and Eligibility 
Subjects will undergo baseline evaluation to determine eligibility for the study.  
 
IGT S ystems EPD CIP Tem plate  Pa ge: 18 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 18 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 After being informed of the nature of the study, th e subject will sign a written informed consent form 
(ICF) that has been approved by the IRB/EC of the clinical site and by the Sponsor. Subjects will be 
considered for the study if they meet the specific inclusion/exclusion criteria. The criteria for enrollment must be fo llowed explicitly.  
 Inclusion Criteria 
1. Subject must be aged >18 years. 
2. Subject must have signed a written Informed Consent form to participate in the study, prior to any 
study related procedures. 
3. Subject must be willing to comply with the protocol requirements. 
4. Subject receives a de novo ablation procedur e for treatment of atrial fibrillation. 
 
 Exclusion Criteria 
1. Pregnant women. 
 
 Withdrawal  
Every effort should be made to retain subject enrolment for the duration of the study. During the 
informed consent process subjects should be fully informed of the data co llection requirements and 
duration and should only be enrolled if willing to fully participate in it. All subjects enrolled in the 
clinical study must be accounted for and doc umented. Reasons for withdrawal may include; 
 Physician discretion 
 Subject choice to retire consent, loss to Follow up, or death. 
In the event that the subject withdraws from the st udy every effort should be made to obtain full 
information on any on-going adverse events.  
The reason for withdrawal must be recorded in th e End of Study (EoS) CRF and in the patient file. All 
open adverse events should be closed or documented as ongoing. Data collected up to the point of 
subject withdrawal may be used, unless any local  regulations prohibits the use of the data. 
 Study Procedures 
 Screening and Informed Consent 
Patients who may be eligible for enrollment will go through the informed consent process. At the 
screening visit, subjects will be approached to obtain written informed co nsent prior to any study 
specific procedures being performed. The purpose of the study and the benefits and risks of the 
procedures will be explained to the subject and the consent process must be documented accordingly 
in the medical record. Subjects who agree to study participation must sign an approved ICF. Subjects will be informed that their participation in this stud y is voluntary and they may refuse to participate or 
discontinue from the study at any time. Subjects will be given the opportunity to ask questions so that 
 
IGT S ystems EPD CIP Tem plate  Pa ge: 19 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 19 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 they are adequately informed about the research. A copy of the signed informed consent must be 
provided to the subject and the informed consen t process will be documente d in source documents. 
Subjects are considered enrolled once their info rmed consent has been correctly documented. 
If new information becomes available that may affect a subject’s decision to continue to take part in 
the study, this information will be discussed with the subject. 
Subjects who are unable or unwilling to provide writ ten informed consent should not be included in 
the investigation.  
The following assessments/procedures will be performed during the screening, following the 
institutions’ standard protocols: 
 Demographics 
 Medical history 
 Physical examinations 
 Concomitant medications 
 Presence/history of atrial fibrillation 
 Previous and current treatments of atrial fibrillation 
 Intervention 
Patient management and treatment decisions are at the discretion of the care team per routine clinical 
practice. The KODEX-EPD system is an open-platform system however all catheters/leads used during the intervention need to be calibrated prior to the intervention.  
 Clinical Workflow 
1) Advance the Achieve spiral mapping catheter (Achieve) to the Left Atrium (LA). 
2) Image the LA with the Achieve by maneuvering the catheter around the LA under different 
angles. 
3) Inflate the Cryoballoon (CB) and advance CB to oc clude the ostium, make sure the location of 
the Achieve is maximal 15 mm distal to the CB. Hold this location for 5 seconds. 
 KODEX-EPD System will obtain a “shadow” of the Achieve at the current location this 
will take approximately 2 seconds. 
 
Please note that there are 2 types of notifications on the KODEX-EPD system that can be 
shown when obtaining the ‘shadow’; 
‐ DTM; When the distance between the Achieve and the Mesh is > 10mm  
‐ DTO; When the distance between the Achieve and the Ostium is > 35mm  
It is recommended to reposition the catheter and acquire a new shadow 
 
4) Verify occlusion on fluoroscopy (in the blinded arm) or KODEX(in the KODEX guided arm) by selective contrast injectio n while simultaneously stepping on the KODEX-EPD System’s 
foot pedal/or the injection button in the KODEX-EPD system is pressed to start the occlusion 
 
IGT S ystems EPD CIP Tem plate  Pa ge: 20 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 20 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 assessment with the KODEX-EPD System. The occlusion assessment will take approximately 
12 seconds. After which the physician should decide to; 
 Proceed with CB ablation and move to next PV 
 Reposition CB and repeat step 4. 
 
Please note that for a succe ssful occlusion assessment on the KODEX-EPD system it is 
important that; 
‐ The there is no DTM, DTO or DTS ( When the distance between the Achieve and the 
Shadow is > 10mm) notification on the KODEX-EPD system 
‐ The injection on the KODEX-EPD system is synced with the actual injection 
‐ The Injection is done with one shot. 
If occlusion is not indicated when assessing occlusion in the KODEX guided arm it is recommended to 
reposition the CB and re-assess the occlusion with KODE X. In total 3 consecutive attempts should be 
made to obtain occlusion on KODEX. 
 
 
It is recommended to use an auto-injector where 6cc is injected at 2.5ml/sec and the 
dye/saline ratio is between 50/50 to 100/0. 
 If a manual syringe is used the injection shou ld be swiftly and the dye/saline ratio needs to 
be between 70/30 to 100/0. The amount of injection is at the physician’s discretion. 
 
Considerations for the use of contrast in this workflow are the following; 
‐ The contrast injection induces a significant local dielectric change and impacts some/all 
readings off the Achieve electrodes. 
‐ The contrast needs to reach and embed the Achieve electrodes. 
‐ Monitor no movement during injection. 
‐ The Achieve’s proximity to the CB will impact the results. 
 
 Data Collection 
The following data will be collected during the intervention: 
 KODEX-EPD data collection 
 Fluoroscopy system data collection 
 Fluoroscopy time 
 Fluoroscopy dose 
 Number of contrast dye injections 
 Contrast dye volume 
 Information on durability of the PV isolation.  
 
IGT S ystems EPD CIP Tem plate  Pa ge: 21 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 21 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
  Time to isolation (TTI) – if possible 
 Number of ablations per vein 
 Procedure time (skin to skin) 
 cineloops of procedural images 
 Cryoconsole freeze data 
 Safety Events 
 
 Follow up  
This is an acute study and there is no follow-up foreseen. 
 Discharge & End of Study 
The End of Study (EoS) is defined as after patien t’s discharge. The following data will be collected 
during the Discharge/EoS visit; 
 Vital signs 
 Concomitant medication 
 Safety Events 
 After End of Study 
After the study participation has ended the subjects will be followed up at the discretion of the 
investigator in accordance with the standard of care.  No additional follow up is intended after Subjects’ 
participation in the study has ended.  
Subject data may be collected after the subjects’ end of study. Following the FDA guidance; all AEs 
and non-study related SAEs should be followed up unt il they have resolved or stabilized or until 30 
days after participants’ EoS. All other SAEs should be followed until resolution or until the condition has stabilized with no further change expected. 
Data collected for the purpose of th is study may be used for future clinical research in the area of 
cardiac ablations.  
 Schedule of Assessments 
Table 1; Schedule of Assessments 
 Screening Intervention Discharge/EoS 
Visit window ≤ - 1 month - - 
Informed consent x   
Medical History x   
Physical Examinations x   
Vital Signs x x x 
Demographics x   
Incl./Excl. Criteria x   
 
IGT S ystems EPD CIP Tem plate  Pa ge: 22 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 22 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 TEE x1 x2  
12-Lead ECG x1 x2  
Fluoroscopy time and dose  x3  
Contrast dye # of injections and volume  x3  
TTI  x  
# of Ablations per PV  x  
Procedure time  x  
cineloops of procedural images  x  
Cryoconsole freeze data  x  
Concomitant Medications x x x 
(S)AE reporting x x x 
 
1 Only collect data when assessment is done per standard of care within 1 months of screening. Assessment doesn’t require 
to be done for the purpose of the study.   
2  Only collect data when assessment is done per standard of care. Assessment doesn’t require to be done for the purpose of 
the study.  
3 Data from 2 intervals;  
1. start of procedure – transseptal puncture  
2. successful transseptal puncture – isolation 
 Standardization of Study Procedures  
 Measurements of Vital Signs 
Blood Pressure (BP) and Heart Rate  (HR) measurements should be determined after the subject has 
been seated for at least 5 minutes. BP should be measured on both arms and the arm with the highest 
systolic reading at screening should be used for BP determination throughout the study. The subject’s pulse should be measured for 30 seconds and the number should be multiplied by 2 to obtain HR.  
 Concomitant Medication 
Targeted concomitant therapy and medications will be recorded on the CRF. The following groups of 
concomitant medications  will be recorded; 
 Anticoagulants 
 Cardiovascular medications 
 Antiarrhythmic medications/substances 
 Procedural Images 
Cineloops of procedural images are to be created  starting just prior to contrast injection for 
fluoroscopic verification of occlusion for a duration of 5 seconds and should include one respiratory cycle. A visual assessment of the occlusion sh ould be made by the physician at that time and 
documented in the procedural notes. The images will  be collected and reviewed for an independent 
assessment. 
 
 
IGT S ystems EPD CIP Tem plate  Pa ge: 23 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 23 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 3. RISK/BENEFIT ANALYSIS  
 Potential Risk to the Subject 
The KODEX-EPD system used in this study is cl eared for commercial use by the FDA and is CE-
certified; therefore, the use described in this protoc ol constitutes a standard clinical use. Information 
related to contraindications, advers e effects, warnings and precautions are included in the device 
instructions for use. Patients enrolled do not bear addi tional clinical risk by participating in this study. 
The sponsor has taken all the necessary precautions and applied the required m itigations, as described 
in the risk analysis document, in order to make even the rarest risk become virtually impossible.  
Nevertheless, potential complications that could be related to the system  include, but are not limited, to 
the following anticipated AEs: 
 Skin allergy due to body external patches 
 Secondary transient hyper-hydrosis due to local skin irritation  
 Local superficial burns (return electrode)  
 Hampering the quality of recorded intra-cardiac elec trical signals that are being transferred to the 
recording system through the KODEX-EPD system (noise introduction) 
 Decreasing the power output of the RF generator; thereby poten tially affecting the generated 
ablation lesions  
 Incorrect reading of the catheter's tip electrode im pedance at rest or during ablation as presented 
on the RF generator front panel 
 Incorrect reading and presentation of the tip electrode temperature as read by the RF generator 
 Incidental electrocution  
 Potential Benefits to the Subject 
No direct benefits to the patient are expected. 
 
 Benefit-Risk Rationale 
The KODEX-EPD and accessories used for the PROOF Study will be commercially available and are 
considered to be SOC for subjects indicated for cryoballoon PVI Procedures. The risks involved with subject participation in this study are essentially the same as those for subjects not participating in the 
study. 
 
 
IGT S ystems EPD CIP Tem plate  Pa ge: 24 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 24 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 4. SAFETY DATA COLLECTION , RECORDING AND REPORTING  
Adverse events and serious adverse events as defi ned below will be captured once the patient has 
signed the informed consent form. However, the primary endpoint analysis will count only adverse 
events for patients that the KODEX-EPD system has been used during the treatment procedure. 
 Definitions 
 Adverse Events (AE) 
Any untoward medical occurrence, uni ntended disease or injury, or untoward clinical signs (including 
abnormal laboratory findings) in subjects, users or other persons, whether or not related to the 
KODEX-EPD system or accessories and whether anticipated or unanticipated. This definition includes events related to the investigational medical device or the comparator. Additionally, this definition includes events related to the procedures involved. 
For users or other persons, this definition is restri cted to events related to  the use of the KODEX-EPD 
system or accessories or comparators. This definition includes events rela ted to the procedures involved.  
 Adverse Device Effect (ADE) 
An adverse event related to the use of KODEX-EPD System or accessories or the comparator. 
This definition includes adverse even ts resulting from insufficient or inadequate instructions for use, 
deployment, implantation, installation, or operation, or any malfunction of the KODEX-EPD System. 
This definition includes any event resulting from use error or from intentional misuse of the KODEX-
EPD System. 
 Serious Adverse Event (SAE) 
The Investigator must decide whether each event meets the definition of a “serious” adverse event 
(SAE).  SAE is defined as any adverse event that: 
 Led to death, 
 Led to a serious deterioration in health of the subject, users or other persons that either: 
‐ Resulted in a life-threatening illness or injury, or 
‐ Resulted in a permanent impairment of a body st ructure or a body function including chronic 
diseases, or 
‐ Required in-patient hospitalization or prolongation of existing hospitalization, or 
‐ Resulted in medical or surgical intervention to prevent life-threatening illness or injury or 
permanent impairment to a body structure or a body function. 
 Led to fetal distress, fetal death, a congenital a bnormality, or birth defect including physical or 
mental impairment 
NOTE: A planned hospitalization for pre-existing conditio n, or a procedure required by the Clinical 
Investigation Plan, without a serious deterioration in health, is not considered to be a SAE. 
 
IGT S ystems EPD CIP Tem plate  Pa ge: 25 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 25 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 
 Serious Adverse Device Effect (SADE) 
An adverse device effect (section 4.1.1) that has resu lted in any of the consequences characteristic of a 
serious adverse event as me ntioned in section 4.1.2. 
 Unanticipated Serious Adve rse Device Event (USADE) 
An unanticipated serious adverse device event (USADE ) is defined as any serious adverse device effect 
which by its nature, incidence, severity or outcome has not been identified in the current version of the 
risk analysis report. 
NOTE: Anticipated: an effect which by its nature, inci dence, severity or outcome has been previously 
identified in the risk analysis report. 
 Device Deficiencies 
A device deficiency is an inadequacy of a medical device related to its identity, quality, durability, 
reliability, usability, safety, or performance, such as  malfunction, misuse or use error and inadequate 
labeling. This definition includes device defici encies related to the KODEX-EPD System or 
accessories or the comparator. 
All KODEX-EPD system device deficiencies will be documented in the CRF. Devices that malfunction 
during the procedure will be analyzed by the sponso r, after appropriate decontamination per hospital 
guidelines.  
Device deficiencies are NOT to be reported as AEs.  However, if there is an AE that results from a 
device deficiency, that specific event wo uld be recorded on the appropriate CRF. 
 Malfunction 
A malfunction is a failure of the KODEX-EPD System or accessories or the comparator to perform in 
accordance with its intended purpose when used in acco rdance with the instructions for use or CIP, or 
IB. 
 Use Error 
A use error can be defined as a user action or la ck of user action while using the KODEX-EPD System 
or comparator that leads to a different result than that intended by the manufacturer or expected by the user. This includes the ability by the user to complete a task.  
NOTE: A malfunction of a medical device that causes an unexpected result is not considered a use 
error, nor does an unexpected physiological response of the patient.  
 Adverse Event Classification 
 Severity Classification 
Severity will be defined according to the following criteria: 
 
IGT S ystems EPD CIP Tem plate  Pa ge: 26 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 26 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 Mild Awareness of event, but easily tolerated 
Moderate Discomfort enough to cause some inte rference with activities of daily living (ADL) 
Severe Incapacitating, with an inability to perform ADL 
 Relationship Classification 
The investigator’s assessment of an AE/SAE's relatio nship to study device is part of the documentation 
process, but it is not a factor in determining what is or is not reported in the study.  If there is any doubt 
as to whether a clinical observation is an AE/SAE , the event should be repo rted. The relationship or 
association of the study device in causing or contribu ting to the AE/SAE will be characterized as one of 
the following: 
 Not Related : No relationship between the AE and the ad ministration of study treatment and a known 
relationship to other etiologies such as concom itant medications, or subject’s clinical state. 
 Possibly Related : An AE that follows a reasonable temporal sequence from the use of the study 
device/procedure and follows a known response patt ern to the study device/procedure but could have 
been produced by the participant’s clinical state or by other therapies. 
 Probably related : An AE that follows a reasonable temporal sequence from the use of the study 
device/procedure; follows a known response patter n to the study device/procedure; and cannot be 
reasonably explained by the known characteristics of  the participant’s clinical state or by other 
therapies. 
 Related : An AE that follows a plausible temporal seque nce fromthe use of the study device/procedure; 
follows a known response pattern to the study device/procedure. The reaction cannot be reasonably explained by the known characteristics of the subjec t’s clinical state or other modes of therapy 
administered to the subject. 
 Unknown ; Given the information available, sequence and timing of events, it is unknown or 
impossible to determine the relationship between the AE and the study device/procedure. 
 Outcome Classification 
Outcome of the event will be defined according to the following:  
 Resolved : The event has fully resolved at the end of the study. 
 Resolved with sequelae : The event has resolved, but retained pathological conditions resulting 
from the prior disease or injury. 
 Continuing : The event is ongoing at the end of the study. 
 Death : This event is determined to  be the cause of death. 
 
IGT S ystems EPD CIP Tem plate  Pa ge: 27 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 27 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 
 Reporting 
 Reporting of AEs and ADEs 
Information about all adverse events, whether volunt eered by the patient, discovered by investigator 
questioning, or detected through physical examination,  laboratory test or other means, will be collected 
and recorded on the Adverse Event e-CRF and followed as appropriate. For the purpose of this study we will selectively collect AEs; meaning that only AEs directly or indirectly related to the EP intervention and/or any cardiac arrhythmia will be  collected. Selective AE 
reporting is in line with the FDA’s approach to a safe ty assessment that is focused on information that 
is useful and adds to current knowledge. As far as possible, each adverse event will also be described by: 
 its duration (start and end dates) 
 the severity 
 its relationship to the study device (unrelated/possible/probable) 
 the action(s) taken 
 Reporting of SAEs SADEs and USADEs 
For the purpose of this study and based on the defin itions above and the requir ements of the European 
authorities the following events are considered repor table events in accordanc e with Annex 7, section 
2.3.5 and 93/42/EEC respectively: 
 Any SAE whether or not consider ed as related to study device 
 Any KODEX-EPD system deficiency that might have led to a SAE if: 
a. Suitable action had not been taken, or 
b. Intervention had not been made, or 
c. If circumstances had been less fortunate 
 New findings /updates in relation to already reported events 
 
All USADEs, SAEs and SADEs, will be reported on sp ecific forms, if applicab le, and forwarded to the 
Sponsor within 24 hours of first awareness of the event. The Investigator is also responsible for 
complying with the applicable local requirements related to adverse event reporting. 
The investigator must complete the appropriate event report form in English, assess the relationship to 
study device/procedure and e-mail the completed form to the Sponsor at: 
EPDEventReporting@philips.com.   
Follow-up information about previously reported US ADEs, SAEs and SADEs must also be reported to 
the Sponsor within 24-hours of receipt. The Follow up information should be reported on a new event report form by referring to the subject and event number. Only new/updated information needs to be 
entered on the event report form. 
 
Original and the duplicate copies of the event report forms must be kept at the study site. The monitor 
will review and collect copies of the complete d event report forms and related documentation. 
 
IGT S ystems EPD CIP Tem plate  Pa ge: 28 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 28 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
  
If the SAE has not been previously documented (new occurrence) and it is thought to be related to 
study device, Sponsor’s Medical Expert may contact the investigator to obtain further information. If warranted, an investigator alert ma y be issued, to inform all investigators involved in any study with 
the same device that this serious adverse event has been reported. 
5. STATISTICAL CONSIDERATION  
 Study Endpoints 
 Primary Endpoints 
1. The accuracy, sensitivity, specificity and po sitive and negative predictive values of the 
KODEX-EPD PV occlusion feature as compared to conventional venographic method of fluoroscopy 
with contrast dye that will be used to guide the procedure. 
2. The success of the freeze when freeze is in itiated based on the assessment of the KODEX-EPD 
PV occlusion feature as compared to the success of the freeze when freeze is initiated based on the assessment with fluoroscopy and contrast dye. 
 Secondary Endpoints 
 KODEX-EPD data collection 
 Fluoroscopy system data collection 
 Fluoroscopy time 
 Fluoroscopy dose 
 Number of contrast dye injections 
 Contrast dye volume 
 Time to isolation (TTI) 
 Number of ablations per vein 
 Procedure time (skin to skin) 
 Analysis Sets 
The Primary Analysis Set (PAS) includes all successful occlusion tests. Successful  is defined as a test 
for which; 
‐ procedural data e.g.: KOPDEX-EPD system data, venograms, and notes are obtained.  
‐ Presence of DTS, DTM or DTO notifications we re documented before obtaining the shadow.  
This analysis set will be used for the primary endpoint analysis. 
 
The Secondary Analysis Set (SAS) includes all PVIs and ablations done. This analysis set 
will be used for the analysis of the secondary endpoints. The ITT (intend to treat) PVs wi ll be used as a secondary analysis of the secondary endpoints. 
 
 
IGT S ystems EPD CIP Tem plate  Pa ge: 29 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 29 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 
 Sample Size Considerations 
The sample size for the 1st primary endpoint was determined at 120 resulting in approximately 30 
subjects to be enrolled in the blinded arm.  The sample size for the 2
nd primary endpoint was estimated using the One-Sided Lower-Limit 
Confidence Intervals for One Proportion approach. Expecting a proportion of 80% with a lower bound 
of the 95% confidence interval of about 70% the sample size is estimated to be 87. 
 A sample size of 87 would require approximately 22 subjects to be enrolled in the KODEX guided arm. 
 
 Statistical Analysis 
 General Approach/Considerations 
Statistical analyses in this data collection study will be  descriptive in nature. No statistical inference is 
planned. Subject disposition, demographics and base line characteristics will be summarized. Summary 
statistics for continuous variables will include  the number of subjects, mean, median, standard 
deviation or standard error, minimum, and maximu m. For categorical variables, the frequency and 
percentage will be given.  
Interim and final analyses will be based on data collected from this study. There will be no imputation 
for missing data. 
 Analysis of Key Study Endpoints 
 Primary Endpoint Analyses 
Results will be summarized by occlusion test, by PV and by patient. 
 Secondary Endpoint Analyses 
Results will be summarized by PV and by patient. 
 Exploratory Endpoint Analyses 
Results will be summarized by occlusion test, by PV and by patient. 
 Data justification 
Systemic error/bias will be minimized by having op erators select subjects from their general patient 
population. Before enrolling subjects, sites/operators will be trained on the study protocol to ensure 
consistency across sites/operators. Subjects will be equally distributed over the 2 sites in the blinded 
arm of the study. 
 Missing Data 
No imputations for missing data will be made. Th is is an acute study with no F/Up foreseen. 
 
IGT S ystems EPD CIP Tem plate  Pa ge: 30 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 30 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 
 Deviations 
Any changes to the planned statistical analyses ma de will be documented in a separate Statistical 
Analysis Plan. Changes from the planned statistical methods will be documented in the clinical study 
report along with a reason for the deviation. Post -hoc analyses may be conducted according to the 
existing data collected, if necessary 
6. STUDY CONDUCT  
 Statement of Compliance 
This study will be conducted in accordance with ISO 14155:2020 Clinical Investigation of Medical 
Devices for Human Subjects-Good Clinical Practice, and the relevant parts of the ICH Guidelines for 
Good Clinical Practice, ethical principles that have their origins in the Declaration of Helsinki, and 
pertinent individual country laws and regulations including but not limited to EU-MDR . The study shall 
not begin until the required approval/favorable opin ion from the Institutional Review Board (IRB)/Ethics 
Committee (EC) and/or regula tory authority has been obtained, if appropriate.  
The Investigator must submit and, where necessary, ob tain approval from the IRB/EC for all subsequent 
protocol amendments and changes to the Informed Consent form.  The Investigator must notify the 
IRB/EC of deviations from the protocol or SAEs a nd USADEs occurring at the site in accordance with 
local procedures. Any additional re quirements imposed by the IRB/EC or regulatory authority shall be 
followed, if appropriate. 
The Investigator is responsible for obtaining annu al IRB/EC approval and renewal throughout the 
duration of the study where applicable.  Copies of the Investigator’s reports and the IRB/EC continuance 
of approval must be provided to the sponsor. 
Insurance shall be provided for the subjects participating in this clinical trial according to local law. 
The clinical study will be sponsored by EPD Solu tions whereas the financial compensation for the 
investigator/site is defined as an Exhi bit to the clinical trial agreement.  
 Source Documents 
Source data is all information, original records of clinical findings, observations, or other activities in a 
clinical trial necessary for the rec onstruction and evaluation of the tria l.  Examples of these original 
documents and data records include but are not limited to: medical records, clinic and office charts, x-
rays, laboratory notes, stud y specific worksheets, memoranda, subjects’ diaries or evaluation checklists, 
recorded data from automated instruments, copies or transcriptions certified after verification as being 
accurate and complete, microfiche s, photographic negatives, microf ilm or magnetic media, subject 
files, and records kept at the pharmacy and at th e laboratories involved in the clinical trial. 
 
IGT S ystems EPD CIP Tem plate  Pa ge: 31 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 31 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 Regulations require that the Investigator maintain information in the subjects’ medical/hospital records 
that corroborate data collected for th e study.  In order to comply with these regulatory requirements, at 
a minimum, the following is a list of information that should be maintained:  
 Medical history/general physical condition of the subject before involvement in the study of a 
sufficient nature to verify the protocol eligibility criteria 
 Dated and signed study/progress notes on the da te of entry into the study documenting the 
following: 
o The general health of the subject; 
o The discussion of the study risks and benefits with the subject; 
o Completion of the informed consent process; 
o A statement that the subject has reviewed, signed,  and received a copy of the Subject Informed 
Consent Form; 
o Adverse Events reported and their continuation or  resolution, including supporting documents 
such as discharge summaries, X-ra y reports, and other test reports; 
o Subject’s general health and medical condition upon completion of, or withdrawal from, the 
study. 
Subject confidentiality will be maintained throughout the clinical study in a manner that assures data can be traced back to the source  documents.  Additionally, subject information will be managed 
according to the Health Insurance Portability and Accountability Act of 1996 (HIPAA). In addition, all 
personal data will be handled in ac cordance with the EU directive e9 5/46/EC and as of 25 May 2018 in 
accordance with the GDPR. All data will be de-ident ified at each site before being entered into EDC. 
Only the investigator and site coordinator will ha ve access to the de-identified data.  The Informed 
Consent Form must include information letting the subject know: 
 What protected health information (PHI) will be collected during the study; 
 Who will have access to that information; 
 Who will use or disclose that information; 
 The rights of the research subject to revoke their authorization for use of their PHI. 
In the event that the subject revokes authorization,  the investigator retains the ability to use all 
information collected prior to the revocation.  The I nvestigator should attempt to  obtain permission to 
collect at least vital status (i.e. that the subject is alive) at the end of their scheduled study period.   
 Data Handling and Record Keeping 
This study will be performed using an electronic da ta capture (EDC) system. The e-CRF will be used 
for data review, data cleaning a nd issuing and resolving queries. This e-CRF is a web-based e-CRF 
which is password protected and is 21 CFR part 11 compliant. The investigator and study site staff will 
receive training and support on the use of the EDC sy stem and will be granted specific user privileges. 
All CRF data are to be completed by the investigat or, study coordinator, or other designated site 
 
IGT S ystems EPD CIP Tem plate  Pa ge: 32 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 32 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 personnel.  The investigator will perform a final review and sign-off at designated times (e.g. study 
exit). 
 Site coordinators will be trained to enter data into a web-based electronic data capture system designed for this study and for maintaining its data. Source data verification between the CRF and the subject’s 
medical records will be completed by a monitor duri ng onsite visits. Monitoring of the data will be 
completed during ongoing remote data reviews.  Th e clinical database will be a closed system, 
allowing for tracking all the data elements and any changes made.   
 
Raw data that is collected from the KODEX-EPD System and other image data collected through 
modalities used for during the standard  of care intervention will be de-i dentified and stored in a secured 
location.  
 
Sponsor will provide the investigat ional site with supplies for se tting up the study files.  Study 
documents must be maintained by the Investigator and Sponsor for the duration of the trial and for a period of at least 15 years after the trial has been formally closed.
 
 Device Accountability 
Although the study does not foresee the provision of study devices, the site will be responsible to 
ensure that all study supplies and patien t records are kept in a secure place. 
No accountability records for the KODEX EPD system and sensors must be maintained when these are purchased through regular commercial channels. Device  accountability is required to be maintained if 
the system and/or sensors are provided for the sole  purpose of the study. If device accountability is 
required the principal investigator shall keep record s documenting the receipt, use, return and disposal 
of the study device, including date of receipt, identification of each study device, the expiry date, the date of use, subject identification, the date of  return of unused, expired or malfunctioning 
investigational devices a nd date on which the inve stigational was returned. 
 Investigator Responsibilities 
The Principal Investigator of an investigational ce nter is responsible for ensuring that the study is 
conducted in accordance with the Clinical Study Agreement, the investigational plan/protocol, ISO 
14155, ethical principles that have their origins in th e Declaration of Helsinki, any conditions of approval 
imposed by the reviewing IRB/EC, and prevailing local and/or country laws and/or regulations, 
whichever affords the greater protection to the subject. 
The Principal Investigator’s responsibilities in clude, but are not limited to, the following.  
 Prior to beginning the study, sign the Investig ator Agreement and Protocol Signature page 
documenting his/her agreement to conduct the study in accordance with the protocol. 
 Provide his/her qualifications and experience to assume responsibilit y for the proper conduct of the 
study and that of key members of the center te am through up-to-date curriculum vitae or other 
 
IGT Systems EPD CIP Template  Page: 33 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 33 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 relevant documentation and disclose potential confli cts of interest, including financial, that may 
interfere with the conduct of the clinical  study or interpretation of results. 
 Make no changes in or deviate from this protocol, except to protect the life and physical well-being 
of a subject in an emergency; document and explain any deviation from the approved protocol that 
occurred during the course of the clinical investigation. 
 Create and maintain source documents throughout the clinical study and ensure their availability with 
direct access during monitoring visits or audits; ensure that all clinical-investigation-related records 
are retained per requirements. 
 Ensure the accuracy, completeness, legibility, and ti meliness of the data reported to the sponsor in 
the CRFs and in all required reports. 
 Record, report, and assess (seriousness and relationsh ip to the device/procedure) every adverse event 
and observed device deficiency. 
 Report to the sponsor, per the protocol requiremen ts, all SAEs and device deficiencies that could 
have led to a USADE. 
 Report to the IRB/EC and regulator y authorities any SAEs and device deficiencies that could have 
led to a USADE, if required by the na tional regulations or this protocol  or by the IRB/EC, and supply 
the sponsor with any additional requested informatio n related to the safety re porting of a particular 
event. 
 Allow the sponsor to perform monitoring and auditing activities, and be accessible to the monitor 
and respond to questions during monitoring visits. 
 Allow and support regulatory authorities and th e IRB/EC when performing auditing activities. 
 Ensure that informed consent is obtained in ac cordance with this protocol and local IRB/EC 
requirements. 
 Provide adequate medical care to a subject during a nd after a subject’s participation in a clinical study 
in the case of adverse events, as described in the Informed Consent Form (ICF). 
 Inform the subject of the nature and possibl e cause of any adverse events experienced. 
 Inform the subject of any new significant findings occurring during the clinical investigation, 
including the need for additional medical care that may be required. 
 Provide the subject with well-defined procedures for possible emergency situations related to the 
clinical study, and make the necessary arrangements  for emergency treatment, Ensure that clinical 
medical records are clearly marked to indicate that the subject is enrolled in this clinical study. 
 Ensure that, if appropriate, subjects enrolled in the clinical investigation are provided with some 
means of showing their participation in the clinical  investigation, together with identification and 
compliance information for concomitant treatment measures (contact address and telephone numbers 
shall be provided). 
 Inform, with the subject’s approval or when required by national regulations, the subject’s personal 
physician about the subject’s participat ion in the clinical investigation. 
 
IGT S ystems EPD CIP Tem plate  Pa ge: 34 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 34 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
  Make all reasonable efforts to ascertain the reas on(s) for a subject’s premature withdrawal from 
clinical investigation while fully respecting the subject’s rights. 
 Ensure that an adequate investigation site team and facilities exist and are maintained and 
documented during the clinical investigation. 
 Ensure that maintenance and calibration of the equi pment relevant for the asse ssment of the clinical 
investigation is appropriately perform ed and documented, where applicable. 
 Delegation of Responsibility 
When specific tasks are delegated by an investigator , included but not limited to conducting the informed 
consent process, the investigator  is responsible for providing ap propriate training and adequate 
supervision of those to whom tasks are delegated.  The investigator is accountable for regulatory 
violations resulting from failure to adequately supervise the conduct of the clinical study.  
 Protocol Deviations 
An Investigator must not make any changes or devi ate from this CIP except to protect the life and 
physical well-being of a subject in an emergency. An investigator shall notify the sponsor and the 
reviewing IRB/EC of any deviation from the investigat ional plan to protect th e life or physical well-
being of a subject in an emergency, and those deviations  which affect the scientific integrity of the clinical 
investigation.  
All deviations from the investigational plan, with the reason for the deviation and the date of occurrence, 
must be documented and reported to the sponsor wi thin 14 days using the appropriate CRF. Sites may 
also be required to report deviations to the IRB/EC , per local guidelines and government regulations.  
Deviations will be reviewed and evaluated on an on going basis and, as necessary, appropriate corrective 
and preventive actions (including notification, center re-training, or discontinua tion) will be put into 
place by the sponsor or its representatives. 
 Sponsor Responsibilities 
 Confidentiality 
All information and data sent to the Sponsor concerning  subjects or their participation in this study will 
be considered confidential by the Sponsor. Only  authorized Sponsor personnel or a Sponsor 
representative will have access to these confidential  records. Authorized regulatory personnel have the 
right to inspect and copy all records pertinent to th is study. Study data collected during this study may 
be used by the Sponsor for the purposes of this study , publication, and to support future research and/or 
other business purposes. All data used in the analysis and reporting of this study will be without 
identifiable reference to specific subject name. 
The Sponsor will keep subjects’ health information confidential in accordance with all applicable laws 
and regulations.  The Sponsor may use subjects’ health information to conduct this study, as well as for additional purposes, such as overs eeing and improving the performance of its device, new medical 
 
IGT S ystems EPD CIP Tem plate  Pa ge: 35 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 35 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 research and proposals for developing new medi cal products or procedures, and other business 
purposes. Information received during the study will no t be used to market to subjects; subject names 
will not be placed on any mailing lists or sold to anyone for marketing purposes.  
 Monitoring 
Monitoring (on-site and remote) will be performed during the study to assess continued compliance with 
the protocol and applicable regulations. In addition, th e monitor verifies that study records are adequately 
maintained, that data are reported in a satisfacto ry manner with respect to timeliness, adequacy, and 
accuracy, and that the Investigator continues to ha ve sufficient staff and fac ilities to conduct the study 
safely and effectively. The Investigator/institution guarantees direct access to original or electronic 
source documents by Sponsor’s personnel, their desi gnees, and appropriate regulatory authorities. 
The study may also be subject to a quality assurance audit by the Sponsor or its designees, as well as 
inspection by appropriate regulatory authorities. It is  important that the Investigator and relevant study 
personnel are available during on-site monitoring visits or audits and that sufficient time is devoted to 
the process. 
 Insurance 
The Sponsor maintains appropriate insurance coverage for clinical trials and will follow applicable 
local compensation laws. Patients will be treated and/or compensated for any study related 
illness/injury in accordance with the information pr ovided in the Insurance section of the Informed 
Consent document. 
 Amendments to the CIP 
Non-significant changes of the CIP may be included (minor logistical or administrative changes not 
effecting the rights, safety and well-being of human subjects or not related to the clinical investigation 
objectives or endpoints), without prior approval. Significant changes (such as device modifications, 
study procedures) shall be discussed with the coordina ting investigators and principal investigator prior 
approval. All changes will be documented with a just ification and described in  the CIP. Changes shall 
be authorized by the IRB/EC and if applicable the Competent Authority before implementation. 
Exempt from this requirement are measures which have  to be taken immediately in order to protect the 
participants. 
7. PUBLICATIONS  
It is Sponsor’s policy to publish th e results of its Clinical Studies. 
This study will be registered on clin icaltrial.gov before first enrollment. 
The publication of the common database will be u nder the direction of EPD. Publication of the 
complete data set will not be a llowed unless approved by the sponsor. 
 
IGT S ystems EPD CIP Tem plate  Pa ge: 36 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 36 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 Individual investigators may publish their own data se ts upon sponsor approval, if it contains data that 
is unique to that center. Otherwise,  this will not be allowed before  the common data sets have been 
published. 
All publications will be reviewed by  the Sponsor in order to assure that no confidential information is 
disclosed. Such confidential info rmation will be published only after the Sponsor’s Intellectual 
Property has been protected. 
8. GENERAL INFORMATION  
 Study Contact Information 
Questions regarding this study should be directed to the clinical study manager. 
Marieke van Bussel 
Veenpluis 6  Building QP 
5684 PC Best, The Netherlands 
Tel +31 (0)6 39267909 
Marieke.van.Bussel@philips.com  
 Retention of Records 
All source documents and CRFs will be kept for a period of 2 years after the later of the following 
dates: the date at which the study is terminated or completed or; the date that  the records are no longer 
required for supporting marketing applications. 
 Study Completion/Termination or Suspension of the Study 
There are no provisions or interim analyses planned th at can result in an early termination of the study. 
The principal investigator, IRB/EC, or regulatory authority may suspend or prematurely terminate 
participation in the clinical study at the investigation sites for which they are responsible.  
Any signs of unknown or increased risks for the subjects will be disc ussed by the sponsor and 
investigator to assess the impact on the subjects and clinical investigation. If suspicion of an 
unacceptable risk to subjects arises during the clinical investigation, or when so instructed by the IRB/EC or regulatory authorities, the sponsor shall su spend the clinical investigation while the risk is 
assessed. 
The sponsor shall terminate the clinic al investigation if an unacceptable risk is confirmed. If suspension 
or premature termination occurs, the terminating party shall justify its decision in writing and promptly 
inform the other parties with whom they are in di rect communication. The principal investigator and 
sponsor shall keep each other informed of any comm unication received from either the IRB/EC or the 
regulatory authority.  
 
IGT S ystems EPD CIP Tem plate  Pa ge: 37 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 37 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 
 Reporting Timelines  
A final report shall be provided to  all reviewing IRBs/ECs, and the pa rticipating Investigators within 6 
months after termin ation/completion. 
 Subject Follow up 
Following an early termination, suspension or st udy completion, patients who are already treated and 
not discharged will be followed up for adverse even ts till discharge from hospital. Patients who are 
already discharged from the hospital will be followed up as per standard of care in the hospital, outside 
the study. 
In addition, all AEs and non-study related SAEs shoul d be followed up until they have resolved or 
stabilized or until 30 days after participants’ EoS. All other SAEs should be followed until resolution or 
until the condition has stabilized with no further change expected.  
 Blinding  
The blind of this investigation will not be broken as the blinding in this study is not of influence on the 
treatment, the risks of the study device or  the benefit risk ratio to the patient. 
  
 
IGT Systems EPD CIP Template  Page: 38 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 38 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
 9. REFERENCES  
 
i Stanley Nattel, j. a. (decembe r 2014). New directions in cardiac arrhythmia management: present 
challenges and future solutions. 30(12), s420–s430. 
 
ii http://www.clevelandclinicmeded.com/medi calpubs/diseasemanagemen t/cardiology/cardiac-
arrhythmias/  retrieved from clevelandclinicmeded.  
 
iii Zatonskaya e.v., m. g. (2017). The prevalence an d clinical significance of cardiac arrhythmias. . 
rational pharmacotherapy in cardiology., 13(3), 403-408 
 
iv Tang dh, g. a. (2014 , feb). Economic burden and di sparities in healthcare resource use among adult 
patients with cardiac arrhythmia. appl he alth econ health policy. , 12(1), 59-71. 
 
v Priori SG, Blomstrom-Lundqvist C, Mazzanti A,  Blom N, Borggrefe M, Camm J, et al. 2015 ESC 
Guidelines for the Management of Patients With Ventricular Arrhythmias and the Prevention of 
Sudden Cardiac Death. Rev Esp Cardiol (Engl Ed). 2016;69(2):176. 
 
vi Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ, et al. 2015 ACC/AHA/HRS 
guideline for the management of adult patients with  supraventricular tachycardia: A Report of the 
American College of Cardiology /American Heart Association Task  Force on Clinical Practice 
Guidelines and the Heart Rhythm Society. Heart rh ythm : the official journal of the Heart Rhythm 
Society. 2016;13(4):e136-221. 
 
vii Calkins H, Reynolds MR, Spector P, Sondhi M, Xu Y, Martin A, et al. Treatment of atrial fibrillation 
with antiarrhythmic drugs or radiofrequency abla tion: two systematic literature reviews and meta-
analyses. Circulation Arrhythmia and electrophysiology. 2009;2(4):349-61.  
viii Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A, et al. Comparison of 
antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controll ed trial. Jama. 2010;303(4):333-40. 
 
ix January CT, Wann LS, Alpert JS, Calkins H,  Cigarroa JE, Cleveland JC, Jr., et al. 2014 
AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the 
American College of Card iology/American Heart Association Task  Force on Practice Guidelines and 
the Heart Rhythm Society. Journal of the Amer ican College of Cardiology. 2014;64(21):e1-76. 
 
x Kuck KH, Ernst S, Cappato R, Braun E, Lang M,  Ben-Haim SA, et al. Nonfluoroscopic endocardial 
catheter mapping of atrial fibrillation. Journal of cardiovascular electrophysiology. 1998;9(8 
Suppl):S57-62.   
xi Ben-Haim SA, Osadchy D,  Schuster I, Gepstein L, Hayam G, Josephson ME. Nonfluoroscopic, in 
vivo navigation and mapping technolog y. Nat Med. 1996;2(12):1393-5. 
 
 
IGT Systems EPD CIP Template  Page: 39 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 39 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
  
xii Stevenson WG, Delacretaz E, Friedman PL, Ellison KE. Identification and ablation of 
macroreentrant ventricular tachycardia with the CARTO electroanatomical mapping system. Pacing 
and clinical electrophysiology : PACE. 1998;21(7):1448-56. 
 
xiii Gepstein L, Hayam G, Ben-Haim SA. A nove l method for nonfluoroscopic catheter-based 
electroanatomical mapping of the heart. In vitro and in vivo accuracy results. Circulation. 
1997;95(6):1611-22. 
 
xiv Maurer T, Kuck KH, First clinic al experience in high resolution imaging of cardiac anatomy using 
the novel wide band magneto-electric mapping system KODEX.  
 
xv Haïssaguerre M, Jaïs P, Shah DC , et al. Spontaneous initiation of atrial fibrillation by ectopic beats 
originating in the pulmonary veins. N. Engl. J. Med. [Internet]. 1998;339:659–666. 
 
xvi Osório et. al. Recent advances in cryoballoon abla tion for atrial fibrillation. Expert Rev. of Med. 
Devices 2019;16;9:799-808. DOI: 10.1080/17434440.2019.1653181 
 
xvii Maurer T, et. Al. High-Resolution Imaging of  LA Anatomy Using a Novel Wide-Band Dielectric 
Mapping System. JACC Clin. EP. DOI : 10.1016/j.jacep.2019.06.020 
 
xviii Romanov et. al.  High-resolution, real-time, a nd nonfluoroscopic 3-dimensional cardiac imaging 
and catheter navigation in humans using a novel dielectric-based system. Heart Rhythm 2019;16;12 
1890-1891. 
xix Cauti, F. M., Rossi, P., Iaia, L., Polselli, M., P ecere, A., & Bianchi, S. (2 021). Accuracy comparison 
of the new and previous Kodex occlus ion tool software versions to assess pulmonary vein occlusion in 
atrial fibrillation cryoablation. European Heart Journal, 42(Supplement_1). 
https://doi.org/10.1093 /eurheartj/ehab724.0386  
 
xx Cauti, F. M., Solimene, F., Stab ile, G., Polselli, M., Schillaci, V ., Arestia, A., Shopova, G., Iaia, L., 
Giannitti, C. M., Rossi, P., & Bianchi, S. (2021). O cclusion tool software for pulmonary vein occlusion 
verification in atrial fibrillation cryoballoon ablation. Pacing and Clinical Electrophysiology: PACE, 
44(1), 63–70. https://doi.org/10.1111/pace.14130  
 
xxi Rillig, A., Rottner, L., Nodorp, M., Lin, T., Weima nn, J., Münkler, P., Dinsha w, L., Schleberger, R., 
Lemoine, M. D., Nies, M., Risius, T., Blankenberg , S., Kirchhof, P., Meyer, C., Reissmann, B., & 
Metzner, A. (2020). Novel Wide-Band Dielectric Imaging System and Occlusion Tool to Guide 
Cryoballoon-Based Pulmonary Ve in Isolation: Feasibility and First Insights. Circulation. Arrhythmia 
and Electrophysiology,  13(12), e009219. https://doi.org/10.1161/CIRCEP.120.009219  
 
xxii Rottner, L., Sinning, C., Reissmann, B., Schleber ger, R., Dinshaw, L., Münkler, P., Meyer, C., 
Blankenberg, S., Rillig, A., & Metzner, A. (2020). Wide-Band Dielectric Imaging and the Novel 
Cryoballoon-Occlusion Tool to Guide Cryoballoon-Ba sed Pulmonary Vein Isolation. Circulation. 
Arrhythmia and Electrophysiology, 13(8), e008507. https://doi.org/10.1161/CIRCEP.120.008507  
 
 
 
IGT Systems EPD CIP Template  Page: 40 of 40 
 
PROOF Study – CIPS640999 - version 4 – 31-Jan-22               Page 40 of 40 
XCT-2000974 rev.00 / 2021 Dec 15  For internal use  Printed copies are uncontrolled unless authenticated 
  
 
  
 
 
 
 
Philips’ proprietary information. Unauthorized use is prohibited. 
 